ECSP19043710A - Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas - Google Patents

Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas

Info

Publication number
ECSP19043710A
ECSP19043710A ECSENADI201943710A ECDI201943710A ECSP19043710A EC SP19043710 A ECSP19043710 A EC SP19043710A EC SENADI201943710 A ECSENADI201943710 A EC SENADI201943710A EC DI201943710 A ECDI201943710 A EC DI201943710A EC SP19043710 A ECSP19043710 A EC SP19043710A
Authority
EC
Ecuador
Prior art keywords
methods
amino acid
liver diseases
treatment
acid compositions
Prior art date
Application number
ECSENADI201943710A
Other languages
English (en)
Inventor
Chung-Wei Lee
Michael Hamill
Raffi Afeyan
Harry Luithardt
David Berry
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of ECSP19043710A publication Critical patent/ECSP19043710A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona composiciones farmacéuticas que comprenden entidades de aminoácidos y sus usos. También se revelan métodos para mejorar la función hepática y para tratar enfermedades hepáticas que comprenden la administración de una cantidad eficaz de las composiciones a un sujeto que lo necesita.
ECSENADI201943710A 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas ECSP19043710A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491773P 2017-04-28 2017-04-28
US201762545322P 2017-08-14 2017-08-14
US201762576267P 2017-10-24 2017-10-24

Publications (1)

Publication Number Publication Date
ECSP19043710A true ECSP19043710A (es) 2019-07-31

Family

ID=60957469

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201943710A ECSP19043710A (es) 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas

Country Status (22)

Country Link
US (7) US11129804B2 (es)
EP (1) EP3554492A1 (es)
JP (2) JP2020504108A (es)
KR (1) KR20190099242A (es)
CN (2) CN115814053A (es)
AU (1) AU2017382170B2 (es)
BR (1) BR112019012529A2 (es)
CA (1) CA3046551A1 (es)
CL (1) CL2019001686A1 (es)
CO (1) CO2019006291A2 (es)
CU (1) CU20190058A7 (es)
EC (1) ECSP19043710A (es)
IL (3) IL296614A (es)
JO (1) JOP20190146A1 (es)
MA (1) MA51451A (es)
MX (2) MX2019007351A (es)
PE (1) PE20191136A1 (es)
PH (1) PH12019501414A1 (es)
SG (1) SG10201913946WA (es)
TW (1) TWI777999B (es)
WO (1) WO2018118941A1 (es)
ZA (1) ZA201903580B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
CN111295186A (zh) * 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗神经元损伤的氨基酸组合物
WO2019204633A1 (en) * 2018-04-18 2019-10-24 Worlds Greatest Ingredients, LP Compositions and methods of use thereof to promote muscle growth and function
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CA3099762A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Methods of manufacturing amino acid compositions
WO2020154397A1 (en) * 2019-01-22 2020-07-30 The Regents Of The University Of California Bile acids and use in disease treatment
CN110037221A (zh) * 2019-05-28 2019-07-23 广州阿米乐生物技术有限公司 一种解酒固体饮料及其制备方法
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
CA3148434A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CA3164005A1 (en) * 2020-03-16 2020-10-28 Taolei Sun Gold clusters (aucs), composition and method for treatment of liver cirrhosis
JP7457827B2 (ja) * 2020-03-16 2024-03-28 武漢広行科学研究有限公司 肝硬変の治療のための銅クラスター及び組成物
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN112394178B (zh) * 2020-11-16 2022-08-05 首都医科大学附属北京朝阳医院 莫西沙星相关肝损伤的生物标志物、试剂盒及应用
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
TW202315605A (zh) * 2021-07-26 2023-04-16 美商胺細拉健康公司 用於治療ｃｏｖｉｄ—１９急性後期後遺症的胺基酸組合物及方法
WO2023208944A1 (en) * 2022-04-25 2023-11-02 Fundació Eurecat Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid

Family Cites Families (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US693094A (en) 1900-08-13 1902-02-11 Hall Signal Co Signal and signaling-circuit.
US2457820A (en) 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
US3012924A (en) 1956-12-17 1961-12-12 Libbey Owens Ford Glass Co Electrically conducting unit
GB1034358A (en) 1963-05-01 1966-06-29 Chugai Pharmaceutical Co Ltd Body-protein-biosynthesis promoting composition
US3832465A (en) 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US3988466A (en) 1973-06-01 1976-10-26 Kyowa Hakko Kogyo Co., Ltd. Prevention of gastric lesions
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE2906034C2 (de) 1979-02-16 1985-03-28 Maggi AG, Kempttal Verfahren zur Gewinnung von L-Leucin, L-Phenylalanin, L-Tyrosin, L-Cystin und von Gemischen aus L-Leucin und L-Isoleucin
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
US4898879A (en) 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
JPS58126767A (ja) 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
US5298493A (en) 1983-04-20 1994-03-29 Clintec Nutrition Co. Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides
CH658165A5 (fr) 1984-01-04 1986-10-31 Nestle Sa Produit alimentaire efficace dans le traitement de la lepre.
US5034377A (en) 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
US4871550A (en) 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FR2618331B1 (fr) 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
DE69103732T2 (de) 1990-11-01 1995-04-06 Sandoz Nutrition Ltd Hochsaures System enthaltende Nahrungsformulierungen.
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5977073A (en) 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5229136A (en) 1992-05-21 1993-07-20 Clintec Nutrition Co. Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
US5276018A (en) 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
DE4229166A1 (de) 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
US5356873A (en) 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
ES2173109T3 (es) 1992-12-23 2002-10-16 Abbott Lab Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas.
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995004529A1 (en) 1993-08-10 1995-02-16 Musashi Pty. Ltd. Composition for treatment of hangovers
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5378722A (en) 1993-12-03 1995-01-03 Clintec Nutrition Co. Nutritional compositions for management of nitrogen metabolism
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
GB9403935D0 (en) 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
IT1275434B (it) 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
JP4280310B2 (ja) 1995-08-10 2009-06-17 佐々木化学工業株式会社 アミノ酸組成剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6087398A (en) 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5716926A (en) 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6096785A (en) 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JPH1053521A (ja) 1996-08-12 1998-02-24 Kagaku Gijutsu Shinko Jigyodan 脳内グルタミン酸の活性抑制剤および活性増強剤
US6544260B1 (en) 1996-08-20 2003-04-08 Oratec Interventions, Inc. Method for treating tissue in arthroscopic environment using precooling and apparatus for same
IT1289754B1 (it) 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
US5817329A (en) 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
AU7764798A (en) 1997-06-02 1998-12-21 Societe Des Produits Nestle S.A. Product and method for providing glutamine
US5849335A (en) 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
US6281244B1 (en) 1997-06-05 2001-08-28 Novartis Nutrition Ag Therapeutic use for glycine
ES2221095T3 (es) 1997-06-05 2004-12-16 Novartis Nutrition Ag Glicina para prevencion o tratamiento del rechazo de transplantes.
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
IT1294227B1 (it) 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
TW473387B (en) 1997-09-30 2002-01-21 Chugai Pharmaceutical Co Ltd Pharmaceutical or food compositions for treating hepatic diseases or improving liver functions
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification
US6103748A (en) 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP2000072669A (ja) 1998-08-24 2000-03-07 Inst Of Physical & Chemical Res アミノ酸・糖組成物
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US20010041187A1 (en) 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6143786A (en) 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6241996B1 (en) 1999-04-09 2001-06-05 Novartis Nutrition Ag Liquid soy nutritional products
EP1176880B1 (en) 1999-04-27 2005-06-01 Aionix Investments Ltd. Supplement for restoring growth hormone levels
AU8003800A (en) 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
GB9929497D0 (en) 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
AU2001257917A1 (en) * 2000-02-01 2001-08-14 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
US6833350B2 (en) 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
KR20030005282A (ko) 2000-04-18 2003-01-17 소시에떼 데 프로듀이 네슬레 소시에떼아노님 영양 모듈
US6391332B1 (en) 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
IT1320782B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
US20030187049A1 (en) 2000-07-04 2003-10-02 Dioguardi Francesco Saverio Compositions based on aminoacids, suitable for improving muscle performance
IT1320783B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US6417293B1 (en) 2000-12-04 2002-07-09 Dow Corning Corporation Thermoplastic silicone elastomers formed from polyester resins
DE10060819A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheramin-Derivaten zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
DE10060818A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheraminen zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
WO2002069964A1 (en) 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
US20040192751A1 (en) 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
ITTO20010580A1 (it) 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
US6864230B2 (en) 2001-07-31 2005-03-08 Novartis Nutrition Ag Glutamine rich dietary composition
AU2002367129A1 (en) 2001-12-25 2003-07-15 Ajinomoto Co., Inc. Organ fibrosis inhibitors
WO2003061639A2 (en) 2002-01-25 2003-07-31 Diamedica Inc. Use of glutathione synthesis stimulating compounds in reducing insulin resistance
JP2003238401A (ja) 2002-02-20 2003-08-27 Ajinomoto Co Inc 疾患の治療、改善又は予防用医薬品及び飲食品
US7338675B2 (en) 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
US20050176827A1 (en) 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
EP1549299B1 (en) 2002-06-05 2014-08-20 IVAX Pharmaceuticals s.r.o. Reduction of gelatin cross-linking
EP1541141A1 (en) 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US7037522B2 (en) 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
JP2004123564A (ja) 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
JP2004182705A (ja) 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US7547450B2 (en) 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
AU2003296176A1 (en) 2002-12-26 2004-07-22 Ajinomoto Co., Inc. Inhibitor for liver cancer onset and progress
JP4989836B2 (ja) 2002-12-26 2012-08-01 大塚製薬株式会社 経口栄養剤
CN100415224C (zh) 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
JP4528925B2 (ja) 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
EP1638418B1 (en) 2003-06-23 2012-08-29 Nestec S.A. Amino acid supplementation for a healthy microbiota ecosystem
JP2005027524A (ja) 2003-07-08 2005-02-03 Ajinomoto Co Inc 経口アミノ酸組成物
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
EP1675480B1 (en) 2003-10-16 2018-06-13 Nestec S.A. Nutritional composition against side effects of chemotherapy of radiotherapy
JPWO2005049006A1 (ja) 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
ES2550608T3 (es) 2003-12-20 2015-11-11 Nestec S.A. Composición nutritiva para la curación de las heridas
WO2005072721A1 (ja) 2004-01-28 2005-08-11 Ajinomoto Co., Inc. 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
AU2004316357C9 (en) 2004-02-27 2010-09-02 Incorporated Administrative Agency National Agriculture And Food Research Organization Food ingredient including enriched free amino acids and their production method
US20050233013A1 (en) 2004-03-02 2005-10-20 Lee Steve S Methods for enhancing the transport of glucose for balancing blood sugar levels
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
WO2005110124A1 (en) 2004-04-15 2005-11-24 Abbott Laboratories Composition and methods for nutritional management of patients with hepatic disease
CN1582912A (zh) 2004-06-10 2005-02-23 武汉启瑞科技发展有限公司 L－鸟氨酸和 l－门冬氨酸组合物
WO2006009975A2 (en) 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
RU2372900C2 (ru) 2004-07-14 2009-11-20 Адзиномото Ко., Инк. Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с
CN101022821B (zh) 2004-07-19 2014-01-29 纽崔西亚公司 天冬氨酸用于调节血中葡萄糖水平的用途
EP1637163A1 (en) 2004-09-21 2006-03-22 Andreas Kluge Indicator of therapeutic compliance
JP5177785B2 (ja) 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
US8389576B2 (en) 2004-11-26 2013-03-05 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20090048153A1 (en) 2004-12-03 2009-02-19 University Of Maryland, Baltimore Composition for treating sulfur mustard toxicity and methods of using same
JPWO2006061992A1 (ja) 2004-12-10 2008-06-05 味の素株式会社 肝疾患予防・治療用組成物
JP5604673B2 (ja) 2005-01-31 2014-10-15 隆宣 山本 中枢神経系の疲労回復又は疲労予防のための組成物
CN1679941A (zh) 2005-02-02 2005-10-12 北京阜康仁生物制药科技有限公司 一种由牛磺酸和治疗肝病的药物组成的复方制剂及其制备方法
CA2537647A1 (en) 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
RU2007137828A (ru) 2005-03-15 2009-04-20 Нестек С.А. (Ch) Питальные композиции для модулирования биодоступности витамина с
JP5290744B2 (ja) 2005-03-21 2013-09-18 アボット・ラボラトリーズ 糖耐性を改善するためのアミノ酸組成物
EP1865944B1 (en) 2005-03-29 2018-08-29 Ajinomoto Co., Inc. Amino acid-containing composition used for preventing or remedying decrease in skeletal muscle mass of aged people, comprising L-leucine
EP2243383A3 (en) 2005-04-06 2011-02-16 Nestec S.A. A method and composition for nutritionally improving glucose control and insulin action
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US20090209647A1 (en) 2005-06-14 2009-08-20 Nestec S.A. Nutritional method
EP2184062A1 (en) 2005-06-22 2010-05-12 Ajinomoto Co., Inc. Use of glutamic acid and a nucleic acid as metabotropic glutamate receptor activators
US20100104548A1 (en) 2005-06-24 2010-04-29 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus
JPWO2007004613A1 (ja) 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
JP5682990B2 (ja) 2005-08-04 2015-03-11 味の素株式会社 酸化型アルブミン低下剤
JP5067160B2 (ja) 2005-08-05 2012-11-07 味の素株式会社 肝癌発生・進展抑制剤
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
BRPI0615381A2 (pt) 2005-08-26 2011-05-17 Nestec Sa composições e métodos para melhorar a integridade vascular funcional, a sobrevivência celular e reduzir a apoptose na isquemia ou após um episódio isquêmico no cérebro
EP1774973A1 (en) 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
EP2340725A1 (en) 2005-10-28 2011-07-06 Nestec S.A. Methods for the use of branched chain amino acids
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
AU2006311685A1 (en) 2005-11-07 2007-05-18 Jaffe, Russell M Compositions for regulating metabolic disorders and methods of use thereof
RU2414897C2 (ru) 2005-11-30 2011-03-27 Нестек С.А. Способы лечения потери мышечной массы
BRPI0620083A2 (pt) 2005-12-19 2011-11-01 Abbott Lab usos de b-hidróxi-b-metilbutirato
BRPI0706389A2 (pt) 2006-01-09 2011-03-22 Nestec Sa tratamento de pacientes estressados
JP2009536016A (ja) 2006-01-20 2009-10-08 インエル ビョルク， アミノ酸を含む食品組成物
ATE475328T1 (de) 2006-01-31 2010-08-15 Nestec Sa Nährstoffzusammensetzung für säuglinge mit niedrigem geburtsgewicht
US20070270355A1 (en) 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
JP5100033B2 (ja) 2006-05-16 2012-12-19 大塚製薬株式会社 消化管及び腎臓の萎縮抑制剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008050277A (ja) 2006-08-22 2008-03-06 Ajinomoto Co Inc 鉄欠乏性貧血症治療用組成物
US9192593B2 (en) 2006-08-30 2015-11-24 Ajinomoto Co., Inc. Amino-acid containing composition for inhibiting accumulation of fat
CA2666871C (en) 2006-10-19 2011-08-30 Nestec S.A. Long term feed - cancer patient
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
GB0624879D0 (en) 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
EP1932437A1 (en) 2006-12-15 2008-06-18 Nestec S.A. Infant formula
CN100518815C (zh) 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CN101332209B (zh) 2007-06-25 2010-12-08 三菱制药（广州）有限公司 治疗肝性脑病的复方氨基酸注射液
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
KR100970664B1 (ko) 2007-10-11 2010-07-15 한화제약주식회사 Ｌ-오르니틴-ｌ-아스파테이트를 함유한 겔제의 제조방법 및그 겔제
EP2057905A1 (en) 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
US20110077198A1 (en) 2007-11-26 2011-03-31 Michael John Tisdale Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CN101214050B (zh) 2007-12-28 2011-08-31 叶高山 一种具有提神、抗疲劳、醒酒功能的保健饮料
WO2009088433A1 (en) 2008-01-04 2009-07-16 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US20090186098A1 (en) 2008-01-18 2009-07-23 Jose Briceno Sports drink composition
ATE523095T1 (de) 2008-01-25 2011-09-15 Cesar Gallia S R L Aminosäurenkonzentrat in wässrigem gel und mittels verdünnung besagten konzentrats mit wasser erhaltenes getränk zur bekämpfung von müdigkeit
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
US20090203606A1 (en) 2008-02-05 2009-08-13 Wolfe Robert R Systems for and Methods of use of Therapeutic Nutrition for the Management of Age-Associated and Age-Specific Health Conditions of the Elderly
ES2483735T3 (es) 2008-02-07 2014-08-07 Nestec S.A. Composiciones y métodos para influir en la recuperación después de una actividad física intensa
EP2098126A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate Bar
EP2098124A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate gel
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
WO2009149196A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc. Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
EP2344147A2 (en) 2008-09-19 2011-07-20 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
EP2165713B1 (en) 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
EP2351562A4 (en) 2008-10-27 2012-09-05 Ajinomoto Kk SOLID SOLUTION OF VALIN, ISOLEUCIN AND LEUCIN AND MANUFACTURING PROCESS THEREFOR
US8362080B2 (en) 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
BRPI1006145B8 (pt) 2009-01-12 2021-05-25 Biokier Inc composição e método para tratamento de diabetes
US20120178672A1 (en) 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010108542A1 (en) 2009-03-25 2010-09-30 Nestec S.A. A natural taste enhancing savoury base and a process for its preparation
LT3686183T (lt) 2009-04-03 2022-11-10 Ocera Therapeutics, Inc. L-ornitino fenilacetatas ir jo gamybos būdai
WO2010126353A1 (en) 2009-04-27 2010-11-04 N.V. Nutricia Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding
US8703719B1 (en) 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
EP3517110A1 (en) 2009-06-08 2019-07-31 UCL Business PLC Treatment of inflammation using l-ornithine phenylacetate
WO2010143939A1 (en) 2009-06-09 2010-12-16 N.V. Nutricia Nutrition for improving muscle strength in elderly
SG177664A1 (en) 2009-07-20 2012-02-28 Nestec Sa Methods of attenuating the loss of functional status
WO2011030104A1 (en) 2009-09-09 2011-03-17 Rajiv Jalan Phenylacetate and/or phenylbutyrate (not ornithine) for reducing portal blood pressure
CN101664384B (zh) 2009-09-18 2011-09-14 杭州市第六人民医院 N-乙酰半胱氨酸盐木糖醇注射液及其制备方法和应用
AU2010298303A1 (en) 2009-09-23 2012-04-12 Biokier, Inc. Composition and method for treatment of diabetes
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
WO2011043647A1 (en) 2009-10-09 2011-04-14 N.V. Nutricia Amino acid composition with improved dispersibility
EP2327316B1 (en) 2009-11-29 2016-11-16 Premier Nutrition Corporation Method of enhancing muscle protein synthesis
EP2327315B1 (en) 2009-11-29 2013-10-09 Nestec S.A. Dosing protocols for increasing protein synthesis in an active individual
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
JP2011132174A (ja) 2009-12-24 2011-07-07 Kirin Holdings Co Ltd 持久力向上剤
WO2011097273A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
WO2011112695A1 (en) 2010-03-12 2011-09-15 Nestec S.A. Compositions for masking the flavor of nutrients and methods for making same
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
US20130210715A1 (en) 2010-04-26 2013-08-15 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
KR101213825B1 (ko) 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
AU2011281035B2 (en) 2010-07-21 2014-10-02 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
US20120020947A1 (en) 2010-07-22 2012-01-26 Northern Innovations And Formulations Corp. Compositions and methods for increasing lean muscle mass after exercise
CN101912394B (zh) 2010-08-06 2013-11-06 岳茂兴 一种用于治疗凝血障碍出血的药物组合物及其用途
AU2011312042B2 (en) 2010-10-06 2015-08-20 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
WO2012088075A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
CA2821312A1 (en) 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
MX348898B (es) 2011-01-25 2017-07-03 Nestec Sa Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
CA2830476C (en) 2011-03-18 2019-09-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
CN102327259A (zh) 2011-03-31 2012-01-25 姜国辉 具有显著化学性肝损伤保护功能的复合生物制剂
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
BR112013026032A2 (pt) 2011-04-12 2016-12-20 Nestec Sa composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
AU2012244750A1 (en) 2011-04-18 2013-10-17 Nestec S.A. Nutritional compositions having alpha-HICA and eicosapentaenoic acid
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
CA2831798A1 (en) 2011-04-21 2012-10-26 Nestec S.A. Nutritional compositions for enhancing performance and methods for making and using same
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
WO2013006658A1 (en) 2011-07-05 2013-01-10 The Brigham And Women's Hospital, Inc. Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide
BR112014002779A2 (pt) 2011-08-08 2017-02-21 Ajinomoto Kk composição contendo aminoácido para o melhoramento da recuperação a partir de fadiga muscular
AU2012299126B2 (en) 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
EP2574333B1 (en) 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
EP2583565A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2583563A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
WO2013075095A1 (en) 2011-11-18 2013-05-23 The Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
WO2013077893A1 (en) 2011-11-21 2013-05-30 Emmaus Medical, Inc. Methods and compositions for the treatment of diabetes and related symptoms
EP2786750B2 (en) 2011-12-02 2023-06-28 EA Pharma Co., Ltd. Agent for reducing adverse side effects of kinase inhibitor
JP6192543B2 (ja) 2012-01-19 2017-09-06 昇一 城武 植物病原細菌用抗菌剤
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013188258A1 (en) 2012-06-11 2013-12-19 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
DK2879523T3 (da) 2012-07-31 2017-01-16 Nestec Sa Ernæringssammensætning til fremme af muskuloskeletalt helbred hos patienter med inflammatorisk tarmsygdom (ibd)
WO2014040963A1 (en) 2012-09-14 2014-03-20 Nestec S.A. Novel flavour compositions with improved flavour and/or flavour shelf-life
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
CN102961377A (zh) 2012-11-08 2013-03-13 湖北一半天制药有限公司 复方氨基酸注射液（20aa）的制备方法
ES2633769T3 (es) 2012-12-04 2017-09-25 Nestec S.A. Hexanoilglicina como biomarcador para la predisposición al aumento de peso y a la obesidad
EP3584308A3 (en) 2013-02-04 2020-03-04 Seres Therapeutics, Inc. Compositions and methods
ES2708756T3 (es) 2013-03-11 2019-04-11 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o el tratamiento de complicaciones pulmonares inducidas por radiación
BR112015023310A2 (pt) 2013-03-15 2017-07-18 Nusirt Sciences Inc composições, métodos e kits para redução de níveis lipídicos
EP2983530A1 (en) 2013-03-26 2016-02-17 Premier Nutrition Corporation Methods for enhancing muscle protein synthesis following concurrent training
US20160051814A1 (en) 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
WO2014191856A1 (en) 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
ES2617035T3 (es) 2013-06-28 2017-06-15 Nestec S.A. Composiciones y métodos para aumentar el rendimiento deportivo
EP3027181A1 (en) 2013-07-31 2016-06-08 Leeds Beckett University Dietary supplement
EP3048904A2 (en) 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
US9913818B2 (en) 2013-10-09 2018-03-13 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US20170027897A1 (en) 2013-10-23 2017-02-02 Whitehead Institute For Biomedical Research mTORC1 MODULATION BY AMINO ACIDS AND USES THEREOF
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
GB2523578A (en) 2014-02-28 2015-09-02 Daniel Nelson A nutritional supplement
WO2015161448A1 (en) 2014-04-22 2015-10-29 Wuhan Ll Science And Technology Development Co., Ltd. Ornithine-containing or aspartate-containing compositions and the uses thereof
CN105092753B (zh) 2014-05-20 2016-09-07 中国科学院大连化学物理研究所 组合型胺类代谢标志物的应用及试剂盒
WO2016003263A1 (en) 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
US10217645B2 (en) 2014-07-25 2019-02-26 Versum Materials Us, Llc Chemical mechanical polishing (CMP) of cobalt-containing substrate
US20160158305A1 (en) 2014-09-19 2016-06-09 Chip E. Thomson Additives and supplements
AU2015332935B2 (en) 2014-10-14 2020-11-26 Société des Produits Nestlé S.A. Improvement in muscle functionality of elderly males
IL281349B (en) 2014-11-24 2022-09-01 Ucl Business Ltd Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments
KR102429451B1 (ko) 2014-12-04 2022-08-04 프로페셔날 디에테틱스 에스.피.에이. 진피 연결 조직 중 섬유엘라스틴 회복을 위한 아미노산 기반의 조성물
WO2016094316A1 (en) 2014-12-08 2016-06-16 Synaptamine, Inc. Anti-rds compounds and method of manufacture and administration thereof to induce dopamine homeostatis
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
CN107106653A (zh) 2015-01-23 2017-08-29 雀巢产品技术援助有限公司 可用于治疗ibd患者的营养组合物
AU2016208545A1 (en) 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Treatment or prevention of inflammation using serine
EP3247344A1 (en) 2015-01-23 2017-11-29 Nestec S.A. Promotion of healing of intestinal mucosa using proline, serine and threonine
CN107209173B (zh) 2015-01-23 2020-02-07 雀巢产品有限公司 用于确定患者的独特的营养需求的方法
WO2016121829A1 (ja) 2015-01-27 2016-08-04 昇一 城武 ナノ粒子を有効成分とする皮膚炎の治療又は予防剤
US20180036270A1 (en) 2015-02-13 2018-02-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A method of protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine
WO2016128576A1 (en) 2015-02-13 2016-08-18 Nestec S.A. Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
FR3032883B1 (fr) * 2015-02-24 2017-03-17 International Nutrition Res Company Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
KR20180006904A (ko) 2015-04-20 2018-01-19 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제형
US10123985B2 (en) 2015-06-08 2018-11-13 Whitehead Institute For Biomedical Research Therapeutic strategies for treating mitochondrial disorders
US20160367509A1 (en) 2015-06-22 2016-12-22 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
AU2016287453A1 (en) 2015-06-30 2017-09-28 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
RU2755478C2 (ru) 2015-07-15 2021-09-16 Юниджен, Инк. Композиции, способы и медицинские композиции для лечения и поддержания здоровья печени
ES2875601T3 (es) 2015-08-14 2021-11-10 Nestle Sa Composiciones alimentarias semihúmedas que mantienen una textura blanda
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
WO2017033272A1 (ja) 2015-08-25 2017-03-02 昇一 城武 優れた植物病害防除効果を有する菌類用抗菌剤
US20170079897A1 (en) 2015-09-20 2017-03-23 Matthew Brissette MINUS Composition for hair application and methods of hair care
AU2016325556B2 (en) 2015-09-25 2023-02-16 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US20170196944A1 (en) 2015-09-28 2017-07-13 Robert Portman Method to reduce muscle atrophy following orthopedic surgery
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
AU2016353350B2 (en) 2015-11-13 2021-09-23 Ocera Therapeutics, Inc. Formulation of L-ornithine phenylacetate
EP3851114A1 (en) 2015-11-20 2021-07-21 Société des Produits Nestlé S.A. Composition comprising micellar whey protein, vitamin d and clacium to improve or maintain muscle
EP3395341A4 (en) 2015-12-21 2019-08-07 Nanjing Jianrong Bio-Technology Co., Ltd. COMPOSITION FOR THE TREATMENT OF NEUROMITRIC DISEASES AND USE THEREOF
JP2019501182A (ja) 2016-01-08 2019-01-17 コロナリーコンセプツ エルエルシー 肝性脳症の処置のための治療剤の食品ベースの送達
GB201600990D0 (en) 2016-01-19 2016-03-02 Abbott Lab Pharmaceutical or nutritional combination
AU2016405864A1 (en) 2016-05-11 2018-12-13 Tsubo Solutions Pty Ltd Confectionery product
CA3024365A1 (en) 2016-05-27 2017-11-30 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
PL238958B1 (pl) 2016-06-29 2021-10-25 Olimp Laboratories Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja aminokwasowa do stosowania przed wysiłkiem fizycznym
US20180015122A1 (en) 2016-07-14 2018-01-18 Companion Supplements, LLC Pharmaceutical composition effective in preventing adverse effects associated with the use of glucocorticoids
US11033522B2 (en) 2016-08-09 2021-06-15 David C Scott Free amino acid preparation and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
CN106632605B (zh) 2016-12-22 2020-06-16 浙江海洋大学 利用金枪鱼下脚料制备的具有肝损伤修复作用的活性肽
KR20190119046A (ko) 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN107242552A (zh) 2017-07-07 2017-10-13 上海东锦食品集团有限公司 具有缓解体力疲劳及增强免疫力功能的保健食品组合物
CN111295186A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗神经元损伤的氨基酸组合物
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
CN108041501A (zh) 2017-12-22 2018-05-18 北京康比特体育科技股份有限公司 一种促进疲劳恢复的蛋白组合物及其制备方法
CA3099762A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Methods of manufacturing amino acid compositions
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
EP3810276A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the reduction or treatment of inflammation
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
JP2021527671A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法
JP2021528420A (ja) 2018-06-20 2021-10-21 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 苦味のあるアミノ酸を含む治療及び健康のための組成物
MA52960A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour la réduction ou le traitement de la fibrose
CN108524453A (zh) 2018-07-05 2018-09-14 扬子江药业集团广州海瑞药业有限公司 一种门冬氨酸鸟氨酸的药物组合物

Also Published As

Publication number Publication date
IL284371B2 (en) 2023-02-01
ZA201903580B (en) 2021-08-25
JOP20190146A1 (ar) 2019-06-18
IL284371A (en) 2021-07-29
CA3046551A1 (en) 2018-06-28
IL267480B (en) 2021-07-29
EP3554492A1 (en) 2019-10-23
IL267480A (en) 2019-08-29
US20190105294A1 (en) 2019-04-11
US20180207118A1 (en) 2018-07-26
SG10201913946WA (en) 2020-03-30
WO2018118941A1 (en) 2018-06-28
CU20190058A7 (es) 2020-02-04
US11129804B2 (en) 2021-09-28
CN110087647B (zh) 2023-06-16
IL284371B (en) 2022-10-01
CN115814053A (zh) 2023-03-21
PE20191136A1 (es) 2019-09-02
CL2019001686A1 (es) 2019-08-30
JP2023029946A (ja) 2023-03-07
US20180169045A1 (en) 2018-06-21
MX2022013517A (es) 2022-11-16
US20240041810A1 (en) 2024-02-08
US20180296516A1 (en) 2018-10-18
AU2017382170A1 (en) 2019-06-13
CO2019006291A2 (es) 2019-06-28
PH12019501414A1 (en) 2019-10-28
BR112019012529A2 (pt) 2019-11-19
CN110087647A (zh) 2019-08-02
US10201513B2 (en) 2019-02-12
TW201834645A (zh) 2018-10-01
KR20190099242A (ko) 2019-08-26
IL296614A (en) 2022-11-01
US20200330417A1 (en) 2020-10-22
MA51451A (fr) 2019-10-23
TWI777999B (zh) 2022-09-21
MX2019007351A (es) 2019-09-05
US10238617B2 (en) 2019-03-26
AU2017382170B2 (en) 2023-11-30
US11602511B2 (en) 2023-03-14
US10471034B2 (en) 2019-11-12
JP2020504108A (ja) 2020-02-06
US20180169044A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112018012707A2 (pt) inibidores da interação de menin-mll
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201790273A1 (ru) Флагеллиновые композиции и их применение
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018007964A (es) Metodos de uso de inhibidores de caspasas en el tratamiento de la enfermedad hepatica.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201891761A1 (ru) Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение
EA201890911A1 (ru) Комбинация тразодона и габапентина для лечения боли
EA201991502A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний печени
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
BR112019002799A8 (pt) Composto, composição farmacêutica, método para tratar um indivíduo tendo uma doença neurodegenerativa, método para tratar um indivíduo tendo a doença de alzheimer e método para tratar um indivíduo tendo uma doença ou condição
BR112019004404A2 (pt) método para tratar, prevenir ou melhorar doença hepática em um animal, e, composição nutricional.
EA202091908A3 (ru) Комбинированная терапия для лечения онкологического заболевания
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном